Abstract ES2-3: Metabolic asymmetry in breast cancer: Implications for personlised medicine

• Published in: Cancer research (Chicago, Ill.) Ill.), 2016-02, Vol.76 (4_Supplement), p.ES2-3-ES2-3
• Main Author: Lisanti, MP
• Format: Article
• Language: English
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.SABCS15-ES2-3

Over the last decade, strong evidence has accumulated that the tumor micro-environment plays a key role in recurrence, metastasis and poor clinical outcome in breast cancer patients. In this context, more recent discoveries indicate that catabolic cancer-associated fibroblasts (CAFs) produce nutrients (lactate, ketone bodies and glutamine) to fuel anabolic mitochondrial metabolism in cancer cells. This new paradigm is known as metabolic-symbiosis or metabolic asymmetry and reflects the co-existence of multiple metabolic compartments in a given tumor. This type of metabolic co-operation in the tumor ecosystem underlies the metabolic heterogeneity found in human breast cancers, and can be used to more effectively predict tumor recurrence, metastasis, drug-resistance and poor clinical outcome, in breast cancer patients. In my talk, I will highlight how this metabolic-symbiosis phenotype could be targeted from a therapeutic point of view, bringing us closer to the goal of personalized medicine. For further information on this topic, please see the following references: Caveolae and signalling in cancer. Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Nat Rev Cancer. 2015 Apr;15(4):225-37. Metabolic asymmetry in cancer: A balancing act that promotes tumor growth. Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Cancer Cell. 2014 Jul 14;26(1):5-7. Power surge: Supporting cells fuel cancer cell mitochondria. Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Cell Metab. 2012 Jan 4;15(1):4-5. Citation Format: Lisanti MP. Metabolic asymmetry in breast cancer: Implications for personlised medicine. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr ES2-3.